Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04136002 · ClinicalTrials.gov registry record

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

A clinical trial of Colorectal Cancer, sponsored by Guardant Health.

Completed
Registry status
44,467
Enrollment target
20
Study locations

NCT04136002 is a study of Colorectal Cancer that has completed, run by Guardant Health. The registered enrollment target is 44,467 participants, above the 1,391-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (3097% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04136002, a study of Colorectal Cancer, has completed, sponsored by Guardant Health.

COMPLETED
Registry status
44,467 participants
Enrollment target
20
Study locations

Study Summary

The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.

Conditions Studied

Colorectal Cancer

Study Locations (20)

Arizona

  • Hope Research Institute - Chandler
  • Southeast Valley Gastroenterology - Chandler
  • Prime Medical Group, LLC - Gilbert
  • Hope Research Institute - Glendale
  • GI Research Associates, LLC - Phoenix
  • "Forty-Third Medical Associates Absolute Clinical Research" - Phoenix
  • Del Sol Research Management, LLC - Tucson
  • Novak Clinical Research - Tucson
  • Del Sol Research Management, LLC - Tuscon

Alabama

  • Pinnacle Research Group, LLC - Anniston
  • Lakeview Clinical Research - Guntersville
  • Medical Affiliated Research Center - Huntsville
  • Jasper Summit Research LLC - Jasper

California

  • Associated Gastroenterology Medical Group - Anaheim
  • InSite Digestive Health Care - Arcadia
  • Gastroenterology - Burlingame
  • Ventura County Gastroenterology Medical Group - Camarillo

Arkansas

  • Preferred Research Partners, Inc - Little Rock
  • Premier Gastroenterology - Little Rock
  • Arkansas Gastroenterology - North Little Rock

Trial Details

FieldValue
Enrollment Target 44,467 participants
Start Date 2019-10-08
Est. Completion 2025-08-05

Sponsor

Guardant Health

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04136002

The ClinicalTrials.gov registry entry for NCT04136002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44,467 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,391-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (3097% higher). The listed sponsor is Guardant Health, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT04136002 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT04136002 about?

NCT04136002 is a clinical study titled "Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode". The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect color...

What is the current status of trial NCT04136002?

This trial is currently completed. The enrollment target is 44,467 participants. The study started on 2019-10-08. Estimated completion is 2025-08-05.

What conditions does trial NCT04136002 study?

This clinical trial studies the following conditions: Colorectal Cancer.

Who is sponsoring clinical trial NCT04136002?

This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04136002 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.